{"filing":{"accession_number":"0001193125-26-257400","cik":"0000034956","ticker":"TENX","company_name":"TENAX THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d69762d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526257400/d69762d8k.htm"},"events":[{"id":6808,"run_id":5965,"accession_number":"0001193125-26-257400","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Tenax Therapeutics' 2026 annual meeting of stockholders held on June 2, 2026. The filing presents voting results for two proposals: (1) election of seven directors to one-year terms, with vote tallies for each nominee (For/Withheld/Broker Non-Votes), and (2) ratification of Cherry Bekaert LLP as independent auditor. The disclosure is material as it documents the outcome of shareholder governance actions and confirms the composition of the board and auditor selection.","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4335,"accession_number":"0001193125-26-257400","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Tenax Therapeutics' 2026 annual meeting of stockholders held on June 2, 2026. The filing presents voting results for two proposals: (1) election of seven directors to one-year terms, with vote tallies for each nominee (For/Withheld/Broker Non-Votes), and (2) ratification of Cherry Bekaert LLP as independent auditor. The disclosure is material as it documents the outcome of shareholder governance actions and confirms the composition of the board and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:33.575233+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4335,"accession_number":"0001193125-26-257400","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Tenax Therapeutics' 2026 annual meeting of stockholders held on June 2, 2026. The filing presents voting results for two proposals: (1) election of seven directors to one-year terms, with vote tallies for each nominee (For/Withheld/Broker Non-Votes), and (2) ratification of Cherry Bekaert LLP as independent auditor. The disclosure is material as it documents the outcome of shareholder governance actions and confirms the composition of the board and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:33.575233+00:00","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-06-04"}]}